Utilizing the T cell immune response to treat non-small cell lung cancer with CRISPR/Cas9 technology

Abstract. Non-small cell lung cancer (NSCLC) has the greatest incidence rate and fatality, among all the lung cancer types. Its treatment has been widely concerned by the research community. Currently, many inhibitors used in clinical practice face drawbacks such as increased drug resistance in cancer cells and failure, as well as relatively high cytotoxicity. They not only fail to have a long-term effect on the lesion may also cause certain damage to normal cells. Therefore, finding a treatment method that cancer cells cannot or are difficult to develop drug resistance, can have long-lasting effects, and has low cytotoxicity is currently the research direction of scholars. CRISPR/Cas9 technology, a widely used and convenient gene editing method, can modify the microenvironment of T cells or cancer cells as a therapy of NSCLC. This article aims to review the current mechanisms of using CRISPR/Cas9 technology to treat NSCLC looking forward to more treatment sites and methods in the future.